Preliminary results from a midstage trial indicate patients treated with Mesoblast's mesenchymal precursor cells experienced greater pain relief and increased function than those treated with hyaluronic acid alone. Patients who received 6 million cells responded better than those in a higher-dose group. The full results could open the door to a late-stage clinical trial.